InflaRx Updates on Planned Phase III Study Design

 

• Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG)
• Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patients
• FDA review of application for emergency use authorization (EUA) of vilobelimab for the treatment of critically ill COVID-19 patients ongoing
• InflaRx’s management team to host investor and business meetings during JPM Week, January 9 – 12, 2023

https://www.biospace.com/article/releases/inflarx-provides-update-on-planned-phase-iii-study-design-in-pyoderma-gangrenosum-with-vilobelimab-and-status-of-its-eua-application-in-critically-ill-covid-19-patients/